Tefibazumab

From WikiMD.org
Jump to navigation Jump to search

Tefibazumab

Tefibazumab (pronounced as te-fi-ba-zu-mab) is a monoclonal antibody designed for the clinical treatment of infections caused by the bacterium Staphylococcus aureus.

Etymology

The term "Tefibazumab" is derived from the International Nonproprietary Names (INN), where "tefi-" represents anti-infectives, "-ba-" indicates bacterial targets, and "-zumab" is a suffix used for humanized antibodies.

Function

Tefibazumab works by binding to the Clumping factor A (ClfA), a virulence factor of Staphylococcus aureus, thereby preventing the bacteria from adhering to platelets and forming clumps. This inhibits the bacteria's ability to hide from the host's immune system, allowing for easier detection and destruction of the bacteria.

Clinical Trials

Tefibazumab has undergone Phase II clinical trials for the prevention of Staphylococcus aureus infections in high-risk patients undergoing hemodialysis. However, the development of Tefibazumab was discontinued after it failed to show significant benefits over placebo in these trials.

Related Terms

  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
  • Staphylococcus aureus: A type of bacteria that can cause different kinds of infections.
  • Clumping factor A (ClfA): A protein on the surface of Staphylococcus aureus that plays a key role in the bacteria's ability to cause disease.
  • Clinical trials: Research studies that involve people. They test whether drugs, medical treatments, or devices are safe and effective.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski